What's New: October 2026 Update

• September 29, 2026: TRIUMPH-1 published in full. The New England Journal of Medicine published the main Phase 3 obesity trial: 2,339 adults, 28.3% average weight loss at 80 weeks on 12 mg if taken as intended, or 25.0% counting everyone randomized.
• September 29, 2026: TRIUMPH-2 published in The Lancet and presented at the EASD meeting. On the same day, Lilly repeated its plan to submit retatrutide to the FDA in the first quarter of 2027.
• September 24, 2026: court hearing on the biologic question. The Seventh Circuit heard Lilly's appeal over whether retatrutide is legally a biologic. No ruling had been published as of October 3, 2026.
• August 2026: limited access before approval. Lilly confirmed it would make retatrutide available to a limited number of patients who meet specific medical criteria and cannot join a trial, through requests from health care providers.
• Unchanged: retatrutide has not been submitted to the FDA, and no national priority voucher has been announced for it.

When Will Retatrutide Be FDA Approved? The Short Answer

Retatrutide is not approved by the FDA, and Lilly has not yet applied for approval. Its plan, announced on July 23, 2026 and repeated on September 29, is to submit an application in the first quarter of 2027. Until the FDA accepts that application and sets a deadline for its decision, there is no approval date — only an estimate of how long the review would take.

That depends on which review track the FDA assigns:

Two other things could move those dates: a national priority voucher, which is designed to shorten review to a matter of months or less, and a court case over whether retatrutide is legally a biologic at all. Both are covered below.

Where Retatrutide Stands in October 2026

All four core Phase 3 trials in Lilly's TRIUMPH program have reported topline results, and two have been published in full: TRIUMPH-1 in the New England Journal of Medicine and TRIUMPH-2, in people with type 2 diabetes, in The Lancet, both in late September 2026. On July 23, 2026, Lilly said it now had the clinical data to support submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea.

All figures are for the 12 mg dose and assume participants took the drug as intended — the efficacy estimand. Weight loss was lower in the two trials that enrolled people with type 2 diabetes or established cardiovascular disease.

Why Lilly Moved the Filing to Early 2027

Lilly had earlier said retatrutide might be submitted by the end of 2026. When it moved the plan to the first quarter of 2027, it said it was completing the chemistry, manufacturing and controls data package the application requires. Lilly repeated the first-quarter 2027 plan on September 29, 2026.

How Long FDA Review Takes

For a new molecule, the FDA's goal under its current user-fee agreement is to act within 10 months of the date it formally files the application, which comes 60 days after the company submits it — about a year in total. With priority review, the goal is 6 months from the filing date, about eight months in total.

A drug can get priority review in two ways. The FDA can grant it to a drug that would offer a significant improvement in treating a serious condition, a decision made when the application is filed. Or the company can redeem a priority review voucher, a transferable voucher from an older FDA program that secures the faster clock for an application of its choice.

Recent weight-loss approvals have all come in well under a year:

• Semaglutide 2.4 mg for weight management — received December 4, 2020, approved June 4, 2021. Novo Nordisk applied a priority review voucher.
• Tirzepatide for weight management — approved November 8, 2023, six months after Lilly completed its submission, with Priority Review and Fast Track designations.
• Higher-dose semaglutide, approved March 19, 2026, and orforglipron, approved April 1, 2026 — both under the national priority voucher program described below.

None of these is a direct guide to retatrutide. It has never been approved for any use and would be reviewed as a new molecule, and whether it will get priority review by either route is not yet known.

Could a National Priority Voucher Speed Retatrutide Up?

Separately from priority review, the FDA's Commissioner's National Priority Voucher program aims to cut review time from 10–12 months to one or two months for medicines the agency considers national priorities.

Two weight-loss drugs have been approved under it so far: higher-dose semaglutide on March 19, 2026, and orforglipron, Lilly's oral GLP-1 pill, on April 1, 2026 — nearly ten months before its standard review deadline. The voucher Lilly was awarded in November 2025 went to orforglipron, not retatrutide.

Lilly's July 23 announcement about retatrutide did not mention a voucher, and none had been announced for retatrutide when this page was last updated. If one were granted, the dates in the first table would no longer apply.

The Legal Fight Over Whether Retatrutide Is a Biologic

Lilly says it will file a Biologics License Application. Whether retatrutide legally counts as a biologic is still unsettled.

For a molecule like retatrutide, the legal question is whether it counts as a protein or as something analogous to a protein; either would make it a biologic. The FDA found that it was neither. In 2025 a federal district court in Indiana upheld the FDA's finding that retatrutide is not a protein — a category defined partly by how many amino acids a molecule contains — but set aside its finding that retatrutide is not analogous to one, and sent that question back to the agency. Lilly appealed to the Seventh Circuit in February 2026, arguing among other things that the FDA had run out of time to decide. The appeals court heard argument on September 24, 2026.

Two things turn on the outcome. A biologic is protected from copies for 12 years; a conventional drug for five. And biologics are not eligible for pharmacy compounding. If retatrutide is not a biologic, Lilly would have to file a New Drug Application instead of the one it has announced, which BioSpace reported could delay approval.

What Could Delay Approval

At the end of a review, the FDA either approves the application or issues a complete response letter setting out what it still needs. A complete response letter is not a final rejection — the company can respond and resubmit — but it adds months.

The safety data the FDA will review include the following; the full picture is in our retatrutide side effects guide.

• Discontinuation. At 12 mg, the share of participants who stopped because of side effects was 11.2% in TRIUMPH-1, according to Table 3 of the published paper (Lilly's May announcement gave 11.3%), 7.7% in TRIUMPH-2, 13.5% in TRIUMPH-3 and 18.2% in TRIUMPH-4.
• Low blood pressure, reported in the TRIUMPH-1 paper in 8.8% of participants on 12 mg against 0.9% on placebo, more often in people also taking blood pressure medicines.
• Dysesthesia, an altered sense of touch: 12.5% at 12 mg against 0.9% on placebo in TRIUMPH-1, and 20.9% against 0.7% in TRIUMPH-4.
• Cardiovascular events in TRIUMPH-3, the trial in people with established cardiovascular disease. Comparing the 9 mg and 12 mg groups combined with placebo, the hazard ratio was 0.82 (95% CI 0.55–1.22) for a five-component measure and 1.12 (0.64–1.96) for the three-component measure. Neither was statistically significant, so the trial does not show whether retatrutide changes cardiovascular risk.

When Will Retatrutide Be Available?

Retatrutide has no release date. It cannot be marketed or sold until the FDA approves it, and Lilly has not said when it would launch after an approval. Before approval, it is available only in two narrow ways. The main one is clinical trials, which are listed on ClinicalTrials.gov; participants in placebo-controlled trials may not receive the drug.

The second is an expanded-access route that Lilly confirmed in August 2026. A company spokesperson said: "For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance." Lilly said it was reviewing requests from health care providers.

Anything sold online as retatrutide is neither of these. Lilly warns that illicit retatrutide products "may contain unknown ingredients, harmful contaminants and impurities." They are not made under pharmaceutical manufacturing oversight and their contents are not verified.

What to Watch for Next

• The Seventh Circuit's decision in Lilly's appeal, argued on September 24, 2026.
• TRIUMPH-5, Lilly's head-to-head trial of retatrutide against tirzepatide, expected to finish around December 2026.
• Lilly's submission, planned for the first quarter of 2027.
• About 60 days later: whether the FDA files the application and on which review track. That is the first point at which a real decision date exists.

Retatrutide Approval Timeline: The Summary

Retatrutide cannot be approved until Lilly submits it, and Lilly's plan is to do that in the first quarter of 2027. The FDA's own review goals then put a decision around the first quarter of 2028 on standard review, or the third or fourth quarter of 2027 on priority review. Those are estimates of when the FDA would decide, not approval dates: no decision date exists until the FDA files the application, and the decision could also be a request for more data. A national priority voucher could bring that forward sharply, but none has been announced for retatrutide. The unresolved question of whether it is legally a biologic could change the type of application Lilly files.

Any launch date quoted before the FDA has filed the application is an estimate. We will update this page when Lilly submits, when the FDA files, and when the court rules.

Sources

• Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025.
• Eli Lilly. What to know about retatrutide. Last updated September 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026.
• Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
• U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027.
• U.S. Food and Drug Administration. Approval letter, NDA 215256 (semaglutide injection 2.4 mg). June 4, 2021.
• U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. November 8, 2023.
• Novo Nordisk. Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management. December 4, 2020.
• U.S. Food and Drug Administration. Commissioner's National Priority Voucher (CNPV) Pilot Program.
• Fierce Biotech. FDA reveals 2nd round of "national priority" voucher winners, including obesity giants Lilly and Novo. November 6, 2025.
• U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher Program. April 1, 2026.
• PharmExec. FDA approves Foundayo under National Priority Voucher Program. April 2026.
• BioPharma Dive. Lilly, with new data, to seek FDA approval of obesity drug retatrutide. July 2026.
• U.S. District Court, Southern District of Indiana. Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503, amended order. October 2025.
• U.S. Court of Appeals for the Seventh Circuit. Eli Lilly and Company v. Robert Kennedy, Jr., No. 26-1301, oral argument. September 24, 2026.
• Food and Drug Law Institute. Eli Lilly & Co. v. Kennedy. June 2026.
• BioSpace. Lilly, FDA retatrutide biologic dispute comes to a head as submission nears. August 5, 2026.
• Reason. Can a new weight loss treatment escape the legal and regulatory thicket? September 10, 2026.
• STAT. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. August 3, 2026.

Medical Disclaimer: This article is for informational purposes only and is not medical or legal advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and products sold online under its name are not sold or supplied by Lilly. Nothing here is a recommendation to use, seek out or avoid any medication. Regulatory timelines described here are estimates based on published FDA goals and may change.